Navigation Links
Inovio Pharmaceuticals' Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
Date:10/5/2011

pable of killing targets in an antigen-specific manner -- a finding that may prove crucial to the success of an effective therapy for HPV-related disease.

Dr. J. Joseph Kim, president and CEO, said, "We greatly appreciate this recognition of Inovio's leadership and innovation in advancing the development of novel vaccines and analytical methods to assess vaccine effects. Our SynCon® vaccines administered with our proprietary electroporation delivery systems have generated best-in-class immune responses in our Phase I clinical trials for cervical dysplasia and HIV. The demonstration of antigen-specific CTL activity induced by Inovio's synthetic vaccines delivered by its proprietary CELLECTRA® electroporation system speaks well for our synthetic vaccine platform in general and in particular for our cancer vaccine programs."

Inovio has active therapeutic vaccine programs for HPV 16 and 18 associated cervical dysplasia/cancer (Phase II), chronic and acute myeloid leukemia (Phase II), prostate cancer (pre-clinical), hepatitis C virus (Phase II), and HIV (Phase I).

About Inovio Pharmaceuticals, Inc.

Inovio is developing its revolutionary synthetic consensus immunogen technologies to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merc
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Massachusetts General Hospital (MGH) Cancer Center has purchased four ... Elekta Infinity and one Elekta Synergy® S. The ... will enable the facility to offer patients a complete cancer ... Infinity systems position MGH to take advantage of ...
... Foundation of America (AAFA) announced today the 2009 Fall Allergy ... 100 most challenging cities for people with fall allergies. ... Wichita, KS (2); Louisville, KY (3); Oklahoma City, OK (4); ... recent AAFA survey, fall is also one of the most ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 3New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 4New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 5New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 6
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... is leading a project to provide technical assistance to ... national HIV strategy and programme of support. The ... the Delegation of the European Commission to Libya. ... LSTM in partnership with Libyan institutions and Harvard University,s ...
... , WALTHAM, Mass., Aug. 4 ... research and advisory firms for pharmaceutical and healthcare issues, ... emerging protease inhibitors, surveyed physicians indicate that they will ... 50 percent of their hepatitis C virus genotype 1-infected ...
... , , COLD SPRING ... the world,s first hand-held, non-contact vein illumination device, announced today that ... to commence European sales of AccuVein,s AV300. , , ... an important step in bringing this beneficial device to healthcare practitioners ...
... High cholesterol, hypertension, diabetes and smoking raise Alzheimer,s risk ... things that are bad for your heart in the ... blood pressure, smoking, diabetes -- are bad for your ... cholesterol levels in midlife were associated with an increased ...
... , NEW YORK, Aug. 4 ... ) announced today that the Company and Alfa Wassermann S.p.A. ... license agreement for Sulonex (sulodexide). Under the terms of the ... US$2,750,000 has already been received by Keryx and $750,000 is ...
... , , , SADDLE ... http://www.kessler-rehab.com ) is the only hospital ... in the country to offer amputees the new PROPRIO FOOT(R), ... users. This advanced bionic technology, developed by Ossur, a global ...
Cached Medicine News:Health News:LSTM leads project to develop HIV/AIDS strategy for Libya 2Health News:Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir 2Health News:Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir 3Health News:AccuVein Vein Illuminator Receives European CE Mark 2Health News:Midlife Heart Risk Factors Linked to Later Dementia 2Health News:Midlife Heart Risk Factors Linked to Later Dementia 3Health News:Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 2Health News:Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann 3Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 2Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 3
... enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative ... serum. The presence of ANA can be ... other laboratory tests to aid in the ... lupus erythematosus, Sjgren's syndrome, scleroderma, and mixed ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... HEp-2000 ANA uses a patented HEp-2 cell ... increase the sensitivity to SS-A/Ro autoantibodies, without ... independent studies have been published worldwide on ... sensitivity to SS-A/Ro autoantibodies when used in ...
Medicine Products: